Curr Urol Rep. 2006 Jan;7(1):23-30.

Minimally invasive management of upper tract urothelial carcinoma.

Source

Department of Urology, University of Iowa, IA 52242-1089, USA.

Abstract

Recently published studies that evaluated minimally invasive treatments for upper tract urothelial cancer (UTUC) were reviewed, including adjuvant topical therapy. Ureteroscopic management remains the initial diagnostic and possibly therapeutic procedure of choice. Percutaneous management is used to treat bulky tumors or tumors that cannot be accessed ureteroscopically. Low-grade UTUC in appropriately selected patients can be safely and effectively treated endoscopically. High-grade disease tends to fail, regardless of treatment modality, and warrants aggressive therapy. Adjuvant therapy seems to be safe, although its efficacy is debatable. Immunotherapy appears to be most effective in patients with upper tract carcinoma in situ.

PMID:: 16480665; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms

Publication Types

Review

MeSH Terms

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies. [Urology. 1999]
Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies.
Grasso M, Fraiman M, Levine M. Urology. 1999 Aug; 54(2):240-6.
Endoscopic management of upper tract urothelial tumors. [Tech Urol. 1997]
Endoscopic management of upper tract urothelial tumors.
Stoller ML, Gentle DL, McDonald MW, Reese JH, Tacker JR, Carroll PR, Best C. Tech Urol. 1997 Fall; 3(3):152-7.
Limitations of ureteroscopy in diagnosis of invasive upper tract urothelial cancer. [Urol Int. 1996]
Limitations of ureteroscopy in diagnosis of invasive upper tract urothelial cancer.
Igawa M, Urakami S, Shiina H, Ishibe T, Matsubara A, Kadena H, Usui T. Urol Int. 1996; 56(1):13-5.
Review Transitional cell carcinoma of the ureter and renal pelvis. [Crit Rev Oncol Hematol. 2003]
Review Transitional cell carcinoma of the ureter and renal pelvis.
Kirkali Z, Tuzel E. Crit Rev Oncol Hematol. 2003 Aug; 47(2):155-69.
Review [Is there a risk of carcinoma dissemination in the percutaneous access for endoscopical treatment of upper urinary tract urothelial tumors?]. [Arch Esp Urol. 2004]
Review [Is there a risk of carcinoma dissemination in the percutaneous access for endoscopical treatment of upper urinary tract urothelial tumors?].
Serrano Pascual A, Fernández González I, González-Peramato P, García González R, Lovaco Castellano F. Arch Esp Urol. 2004 Apr; 57(3):283-90.

See reviews... See all...

Cited by 1 PubMed Central article

Review of topical treatment of upper tract urothelial carcinoma. [Adv Urol. 2009]
Review of topical treatment of upper tract urothelial carcinoma.
Nepple KG, Joudi FN, O'Donnell MA. Adv Urol. 2009; :472831. Epub 2008 Nov 5.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Minimally invasive management of upper tract urothelial carcinoma.
Minimally invasive management of upper tract urothelial carcinoma.
Curr Urol Rep. 2006 Jan ;7(1):23-30.

PubMed
Cognitive executive function in Down's syndrome.
Cognitive executive function in Down's syndrome.
Br J Clin Psychol. 2006 Mar ;45(Pt 1):5-17.

PubMed
Private provider participation in statewide immunization registries.
Private provider participation in statewide immunization registries.
BMC Public Health. 2006 Feb 15 ;6:33.

PubMed
Cytokine signalling in embryonic stem cells.
Cytokine signalling in embryonic stem cells.
APMIS. 2005 Nov-Dec ;113(11-12):756-72.

PubMed
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with hi...
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
J Med Chem. 2006 Feb 23 ;49(4):1379-87.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: